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In the present work we have devised the synthesis of a novel promising carbon nanotube carrier 
for the targeted delivery of radioactivity, through a combination of endohedral and exohedral 
functionalization. Steam-purified single-walled carbon nanotubes (SWCNTs) have been initially 
filled with radioactive analogues (i.e. metal halides) and sealed by high temperature treatment, 
affording closed-ended CNTs with the filling material confined in the inner cavity. The external 
functionalization of these filled CNTs was then achieved by nitrene cycloaddition and followed by 
the derivatization with a monoclonal antibody (Cetuximab) targeting the epidermal growth factor 
receptor (EGFR), overexpressed by several cancer cells. The targeting efficiency of the so-
obtained conjugate was evaluated by immunostaining with a secondary antibody and by incubation 
of the CNTs with EGFR positive cells (U87-EGFR+), followed by flow cytometry, confocal 
microscopy or elemental analyses. We demonstrated that our filled and functionalized CNTs can 
internalize more efficiently in EGFR positive cancer cells. 
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INTRODUCTION 
Carbon nanotubes (CNTs) have shown many applications in the biomedical field thanks to their 
properties and the combination with covalent and/or non-covalent functionalization.1–4 For example, 
they have been employed as ultra-sensitive biosensors for glucose and DNA, nanocomposites for 
prosthetic devices or as drug delivery systems.2,4–6 To this purpose, their high surface area can be 
exploited to append multiple copies of bioactive and/or imaging molecules, creating an appropriate 
platform for the delivery of diagnostic and therapeutic agents. Moreover, their unique electrical, 
thermal and spectroscopic properties in the biological context offer further advantages in the 
detection, monitoring and therapy of diseases. 
In contrast with the numerous and varied reports of CNT-conjugates for drug and gene delivery,5–7 
only few studies exploring CNTs as carriers of radionuclides, either for imaging or therapeutic 
purposes, have been published. We were among the first to trace in vivo a radioactive CNT 
construct obtained by chelation of 111In (i.e. γ-emitter) to single-walled CNTs (SWCNTs) 
functionalized with the chelating molecule DTPA (diethylenetriamine pentaacetic acid).8 With a 
similar approach, Ruggiero et al. radiolabeled CNTs with 225Ac (i.e. α-emitter) and further 
functionalized with an antibody targeting the tumor neovasculature, achieving high tumor 
accumulation and reduction of the tumor volume of xenografted mice.9 Other examples of CNT 
radioimmuno-carriers have been reported combining CNT delivery properties with targeting 
antibodies and radionuclides, such as 86Y, 125I, 14C, 64Cu or 99mTc,10–14 enabling radioimaging and 
even anticancer therapy. Wang et al. recently synthesized hybrids of multi-walled CNTs 
(MWCNTs) and magnetic nanoparticles, and further tethered technetium-99m, achieving dual MRI 
and SPECT imaging.14 In 2010, we reported an innovative example of CNT-based radiotracer 
obtained by exploiting the hollow interior of the tubes to encapsulate the radionuclide (i.e. sodium 
iodide-125, Auger and γ-emitter).15 The encapsulation of the metal halide by molten-phase 
capillary filling at high temperatures engendered sealed nanotubes with the internal material 
trapped inside (Na125I@SWCNTs). The subsequent external functionalization of the CNTs with 
glycoconjugates enhanced the dispersibility and biocompatibility of the construct, which by 
SPECT/CT showed a different biodistribution profile in mice compared to free iodine. We also 
demonstrated that this CNT conjugate allowed the localized and safe delivery of an unprecedented 
radiodosage and remained stable in the biological milieu in vitro and in vivo without leakages of the 
radionuclide. These promising results prompted us to carry out further investigations by exploring 
the possibility to employ a different filling material, functionalization approach and targeting moiety 
to prepare a CNT-carrier for the targeted delivery of radiotherapy. Indeed, the choice of the filling 
radionuclide allows to tailor a specific radiation, cancer type and therapy. In parallel, the 
functionalization of the external surface offers versatility towards the appendage of targeting 
functionalities, thus enabling to modulate the biodistribution of the carrier. The monoclonal antibody 
(mAb) Cetuximab (Erbitux®) was selected as targeting agent for the functionalization of the filled 
nanotubes. This mAb has shown to efficiently target and inhibit the epidermal growth factor 
receptor (EGFR), a membrane receptor regulating multiple cellular processes and overexpressed 
in many cancer types.16 The clinical use of Cetuximab has been approved for the treatment of 
advanced chemo-refractory cancers such as colorectal cancer, non-small-cell lung cancer, head 
and neck cancer.17–19 Moreover, the conjugation of radionuclides to Cetuximab via metal chelation 
has been already investigated, with the goal of enhancing its therapeutic efficacy and achieve 
simultaneous tumor diagnosis and treatment.20 A few examples of Cetuximab-CNT conjugates 
have also been reported,21–23 showing good targeting properties toward EGFR-overexpressing 
cells. However, to the best of our knowledge, no example of radioactivity delivery by means of 
Cetuximab-labeled CNTs has been ever reported. It seemed to us very interesting to exploit the 
high targeting efficiency of this mAb to direct filled CNTs to specific tumor tissues. This 
investigation was carried out as a proof-of-concept using CNTs filled with model non-radioactive 
materials, with the aim of translating the whole process on radioactively-filled CNTs in a second 
phase. We studied a simple and quick protocol for the preparation of mAb-functionalized filled 
CNTs, taking care to keep the time of preparation as short as possible and to preserve the integrity 
of the nanotube structure, to avoid any leakage of the internal material. In order to tether the 
antibody to the nanotubes through a covalent approach, the CNT external surface was initially 
functionalized by a cycloaddition reaction with a suitable linker. The immobilization of the bioactive 
target onto the CNTs through a fully covalent approach was meant to ensure the in vivo stability of 
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the final conjugate. The antibody-CNTs were then thoroughly characterized by different 
techniques, and their targeting ability was assessed in vitro in cancer cells overexpressing EGFR 
(U87 EGFR+). We demonstrated that our novel CNT-carrier is able to selectively accumulate into 
U87 cancer cells, while it is not uptaken by cancer cells which do not express this receptor. 
 
 
RESULTS AND DISCUSSION 
In the last decades, filled CNTs have found applicability in different areas,24–26 particularly receiving 
increasing attention from the biomedical field, since their inner cavity can be occupied by 
therapeutic or imaging cargos, while the outer surface can be modified to convey dispersibility, 
biocompatibility and site-selectivity.26,27 The filling of carbon nanotubes with inorganic compounds, 
in the present case metal halides, can be achieved by molten-phase capillary wetting.28,29 Once 
filled, the process of cooling the system back to room temperature causes the dangling bonds at 
the ends of the nanotubes to seal by radical recombination.30 As a consequence, filled and sealed 
nanotubes are obtained, where the selected material is confined in the inner cavity. 
 
 
 
SWCNT purification and filling 
As-received single-walled CNTs (SWCNTs) were end-opened and purified prior to be filled with the 
selected payloads. Steam was employed as one of the purification steps, since it opens the ends 
of the SWCNTs, decreases the number of structural defects and removes carbonaceous 
impurities.31 The removal of the amorphous carbon allows an efficient sidewall functionalization of 
the tubes.32 Thermogravimetric analyses (TGA) of both the as-received and purified SWCNTs 
performed under flowing air allowed to quantify the amount of inorganic impurities in the samples, 
coming from the synthesis of the nanotubes. Compared to as-received material, which reveals 4.6 
wt % of inorganic solid residue, a decrease is observed for the purified samples down to 1.7-1.9 wt 
% (see ESI Figure S1). 
Opened-ended and purified SWCNTs were next filled with two selected payloads, namely SmCl3 
and LuCl3. The metal halides were encapsulated by molten phase high temperature filling, which 
results in the formation of filled closed-ended CNTs.30 The closed CNT ends allow the removal of 
the external material, using an appropriate solvent, whilst preserving the encapsulated compounds. 
The residue obtained after TGA of filled SWCNTs will still contain a fraction of the inorganic 
impurities present in the purified material but its major contribution now arises from the oxidation of 
the metal halides to the respective metal oxides (Sm2O3 and Lu2O3, respectively) (see ESI Figure 
S1). From the performed thermogravimetric analyses it was possible to determine the filling yield of 
the encapsulated materials employing a previously reported formula.33 In the present case, the 
filling yield of SmCl3@SWCNTs (1a) and LuCl3@SWCNTs (1b) turned out to be 18.1 wt % and 
29.9 wt %, respectively (see ESI Figure S1).  
The encapsulation of the metal halides into SWCNTs was confirmed by electron microscopy 
imaging and spectroscopy. First, high angle annular dark field scanning transmission electron 
micrographs (HAADF-STEM) were acquired on a scanning electron microscope (SEM) operated at 
20 kV (Figure 1a, b).  
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Figure 1 HAADF-STEM images of (a) LuCl3@SWCNTs (1b) and (b) SmCl3@SWCNTs (1a); EDX spectrum of 
(c) LuCl3@SWCNTs (1b) and (d) SmCl3@SWCNTs (1a). The Cu peaks arise from the grid employed for the 
analysis. 
 
 
Imaging at low operating voltages prevents the damage of carbon nanotubes by electron beam 
irradiation. HAADF-STEM imaging is a powerful tool that allows the direct visualization of the 
encapsulated material.34 Since the contrast formation of the image is proportional to the atomic 
number of the element, heavy elements such as lutetium and samarium appear much brighter than 
carbon from the SWCNTs. Therefore, the bright lines observed on the images correspond to LuCl3 
and SmCl3. As it can be seen, these bright lines follow the shape of the SWCNTs, an indication of 
the successful encapsulation of the payloads. To further confirm the presence of the metal 
chlorides and assess the purity of the prepared samples, energy dispersive X-ray (EDX) spectra 
were acquired using a transmission electron microscope (Figure 1c, d). EDX analysis reveals the 
presence of either LuCl3 or SmCl3 and the absence of impurities apart from a small amount of iron 
visible in the LuCl3@SWCNT sample. This Fe content can be attributed to residual catalyst 
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nanoparticles used for the growth of the SWCNTs still present after the purification of the 
SWCNTs. Direct evidence of the confinement of the investigated materials inside carbon 
nanotubes was provided by high resolution TEM imaging (see ESI Figure S2).  
 
Functionalization of Sm-filled SWCNTs 
The functionalization of the external surface of filled SWCNTs was then performed by nitrene 
reaction. This is a [2+1] cycloaddition involving reactive nitrenes leading to the formation of 
aziridine rings on the CNT sidewalls.35,36 This reaction does not require harsh conditions and 
occurs at the unsaturated bonds of the nanotubes, without engendering major defects and thus 
preserving the sealed structure of the nanotubes. The functionalization of nanotubes by nitrene 
reaction has been reported, either using azidocarbonates35 or organic azides36 as starting material, 
and affording good degree of functionalization in both cases. As precursor for the nitrene reaction 
we employed the organic azide S3, which bears the reacting azide group at one terminus, a 
phthalimide-protected amino group at the other terminus connected by a triethylene glycol (TEG) 
chain (Scheme 1). Though TEG is a short chain, its hydrophilic character can enhance the 
nanotube water-dispersibility upon functionalization. Furthermore, the use of short ethylene glycol 
chains offers the advantage of minimizing the adsorption phenomena and facilitates the thorough 
removal of unreacted precursor with a shorter work-up, compared to longer ethylene glycol chains. 
The azide precursor S3 was synthesized starting from commercially available 
[(chloroethoxy)ethoxy]ethanol, according to a reported procedure (see ESI Scheme S1).37  
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Scheme 1 Nitrene reaction on SmCl3@SWCNT (1a) and cleavage of the phthalimide group to afford the amino 
functionalized SmCl3@SWCNT-NH2 (3a). 
 
For nitrene reaction, SmCl3@SWCNTs (1a) were dispersed in dry NMP by sonication under inert 
atmosphere and, after addition of a 20-fold mass excess of azide S3, the mixture was reacted at 
200°C for 12 hours (Scheme 1). As nitrene reaction can proceed also by radical addition, it is 
important to ensure an inert atmosphere within the reaction vessels, to prevent the highly reactive 
species from reacting with oxygen.38 The work-up of the reaction was carried out with thorough 
washing of compound 1a and dialysis against ddH2O (to remove the adsorbed TEG chain). The 
phthalimide protecting group was cleaved by treating with hydrazine a dispersion of 
SmCl3@SWCNT-Pht (2a) in ethanol (Scheme 1). The loading of free amines determined by 
colorimetric Kaiser test was 90 μmol/g, corresponding to 110 μmol/g of carbon taking into account 
the filling yield. The amine-functionalized CNTs (3a) and the Pht-protected precursor (2a) were 
also characterized by TGA performed this time under inert atmosphere, confirming the occurrence 
of the functionalization (see ESI Figure S3). In order to have a further proof of the presence of free 
amines on functionalized SWCNTs and of their availability for further derivatization, we coupled the 
amines with an iodinated tagging molecule to enable atomic-scale detection by Z-contrast 
STEM.15,39 The results of this experiment are described in detail in the ESI. 
Synthesis and characterization of filled SWCNT-antibody conjugates 
In a recent report, Bonifazi and co-workers succeeded in conjugating Cetuximab to functionalized 
MWCNTs by carbodiimide-assisted amidation between the carboxylic groups on the antibody and 
the amino groups present onto CNTs.21 Molecular dynamics simulations of the structure of 
Cetuximab revealed that 40% of carboxylic acids are buried in the mAb tertiary structure, while the 
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remaining 60% is homogenously distributed on the outer surface and therefore potentially reactive 
toward amidation reactions with amines.21 Their approach seemed convenient to us, as our 
functionalized SWCNTs do also display free amino groups on the sidewalls and this would allow to 
achieve the final conjugate in only one step. Amino-functionalized SmCl3@SWCNT-NH2 (3a) were 
thus incubated for 24 h with Cetuximab in the presence of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC×HCl) and N-hydroxysulfosuccinimide (NHSS) in buffer 
conditions (Scheme 2). Since proteins can have a strong affinity for CNTs, we carried out a control 
reaction to check if non-covalent immobilization of the antibody also occurred. For this purpose, the 
conjugate SmCl3@SWCNT-NH2 (3a) was mixed with Cetuximab in the absence of coupling 
reagents (Scheme 2), under the same conditions of the covalent reaction. 
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Scheme 2 Covalent derivatization of SmCl3@SWCNT-NH2 (3a) with Cetuximab forming SmCl3@SWCNT-mAb (4a) and 
control reaction in the absence of coupling reagents forming the non-covalent complex SmCl3@SWCNT/mAb (5a). 
By comparing the weight loss of SmCl3@SWCNT-mAb (4a) (obtained by covalent amidation) with 
that of the precursor (3a), we estimated that the loading of antibody on SWCNTs was 250 mg/g 
(407 mg/g of C, taking into account the filling yield) (Figure 2). However, the TG curve of the non-
covalent conjugate SmCl3@SWCNT/mAb (5a) also displayed a significant weight loss, which 
corresponds to a loading of mAb of 200 mg/g (305 mg/g of C). This result suggests that a non-
negligible amount of antibody is absorbed onto the nanotubes and could not be removed despite 
the thorough washing and dialysis steps. However, SmCl3@SWCNT-mAb (4a) was remarkably 
well-dispersed in PBS buffer, and the dispersion was stable for longer time compared to the 
corresponding non-covalent conjugate (5a).  
        
Figure 2 TG curves of pristine SmCl3@SWCNTs and conjugates SmCl3@SWCNT-NH2 (3a), SmCl3@SWCNT-mAb (4a) 
and SmCl3@SWCNT/mAb (5a). The percentages correspond to the weight loss observed at 650°C. 
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The mAb immobilization was then evaluated by gel electrophoresis for both SmCl3@SWCNT-mAb 
(4a) and SmCl3@SWCNT/mAb (5a) under non-reducing conditions (Figure 3). In the case of the 
non-covalent conjugate (5a) (lane 4), the unbound antibody is free to migrate through the gel, and 
the corresponding band is clearly visible at the correct size position (ca. 150 kDa). Whereas, for 
the covalent conjugate (4a), no distinct band can be seen in correspondence to the mAb position. 
This suggests that for SmCl3@SWCNT-mAb (4a), most of Cetuximab is covalently bound to the 
CNTs, and cannot therefore migrate through the gel. However, the presence of a small amount of 
non-conjugated mAb cannot be excluded, and it is probably responsible for the light shadows 
visible in lane 3. 
 
Figure 3 Gel electrophoresis of Cetuximab and conjugates SmCl3@SWCNT-mAb (4a) and SmCl3@SWCNT/mAb (5a) 
run under non-reducing conditions at 150 V. Gel stained with Coomassie blue. Protein ladder is on lane 1 (molecular 
weights are expressed in kDa). 
 
We further characterized both antibody-SWCNT conjugates by electron microscopy, performing an 
immunostaining with a secondary antibody conjugated with gold nanoparticles (AuNPs). This 
experiment had the double goal of allowing to visualize the Cetuximab attached to the nanotubes 
and to prove its ability to recognize a specific anti-antibody. The antibody-functionalized conjugate 
SmCl3@SWCNT-mAb (4a) and the control complex SmCl3@SWCNT/mAb (5a) were stained with 
an anti-human IgG linked with colloidal AuNPs of 15 nm in diameter, able to recognize Cetuximab. 
As a further control, the same samples were separately stained with an anti-rabbit IgG/AuNPs (15 
nm diameter), which instead is not specific toward human IgGs. By TEM imaging of 
SmCl3@SWCNT-mAb (4a) stained with anti-human IgG/AuNPs, a multitude of black dots 
corresponding to the AuNPs were visible all along the nanotubes (Figure 4). In the corresponding 
HAADF STEM images it is possible to distinctly recognize both the AuNPs as bright large dots, and 
the samarium-filling. Almost no AuNPs are visible in the images corresponding to 
SmCl3@SWCNT-mAb (4a) incubated with the anti-rabbit IgG, proving that there is no unspecific 
binding between this secondary antibody and Cetuximab, neither adsorption of the IgG onto the 
CNTs. Interestingly, for the non-covalent conjugate (5a) we did not observe any specific labeling of 
the secondary anti-human IgG (Figure 4). We hypothesize that the binding sites of the adsorbed 
Ab might be masked and unavailable to the secondary Ab recognition. Overall, these results 
support our objectives, since only the conjugate obtained by covalent reaction displays clear 
targeting ability. 
170
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Figure 4 TEM images (top row) and HAADF STEM images (bottom row) of conjugate SmCl3@SWCNT-mAb (4a) after 
staining with an anti-human and an anti-rabbit IgG/AuNPs, and of non-covalent conjugate SmCl3@SWCNT/mAb (5a) 
after staining with anti-human IgG/AuNPs. 
 
Further characterization of SmCl3@SWCNT-mAb (4a) stained with anti-human IgG was performed 
by EDX analysis and EDX elemental mapping, confirming the presence of both Au and Sm, and 
their location in the analyzed area (Figure 5). By this immunostaining experiment we could 
therefore prove that Cetuximab was efficiently immobilized on the Sm-filled SWCNTs and that its 
affinity toward an appropriate secondary antibody was preserved upon conjugation. 
 
Figure 5 (a) HAADF STEM image of conjugate of SmCl3@SWCNT-mAb (4a) after staining with an anti-human 
IgG/AuNPs and (b) its EDX analysis.(c-f) STEM-EDX mapping on sample (4a). (d) HAADF intensity, (e) Au and (f) Sm 
mapping on the rectangle area in (c). 
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Targeting studies using filled SWCNT-antibody conjugates 
With the aim of testing the targeting capability of the antibody-functionalized SWCNTs, U87 
glioblastoma cells modified to overexpress EGFR (U87-EGFR+) and Chinese hamster ovary cells 
(CHO) were selected, the latter chosen as a negative control as they do not express EGFR (see 
ESI Figure S7).40 This important difference between these two cell lines allowed us to compare the 
uptake and binding of the nanotubes with a focus on their targeting effect. For this purpose, U87-
EGFR+ and CHO were treated for 1 and 3 hours with 10 µg/ml of CNTs. As a positive control a 
concentration of 2.5 µg/ml of Cetuximab was used. After the incubation time, the cells were 
washed, fixed and treated with the Cy3-goat anti-human IgG (H+L) fluorescent secondary antibody 
binding Cetuximab, to allow the analysis of the cellular binding and uptake by flow cytometry. As 
shown in Figure 6, more than 80% of U87-EGFR+ were able to bind and internalize Cetuximab 
covalently or non-covalently bound to SWCNTs, whereas the same behavior occurred in less than 
5% of the CHO cells in every case. The absence of binding and uptake of the SmCl3@SWCNT-
NH2 (3a) confirms the specificity of the interaction occurring only in the presence of Cetuximab and 
exclude a non-specific adsorption of the secondary antibody on the amino-functionalized CNTs, 
thus confirming the results of the immunostaining (Figure 4). 
 
Figure 6 Intracellular uptake of the different functionalized SmCl3@SWCNTs in U87-EGFR+ cells (top) and 
CHO cells (bottom) after 1 h and 3 h treatment. Cellular uptake was assessed by analyzing the percentage of 
positive cells for Cetuximab. NT: Non treated cells. 
 
These results show that CHO and U87-EGFR+ cells act as good models to analyze the targeting 
effect and that Cetuximab is in fact targeting the EGFR. In this case, no differences were detected 
between SmCl3@SWCNT-mAb (4a) and SmCl3@SWCNT/mAb (5a), which may indicate that the 
mAb contributed to the targeting in both cases, but probably in a different manner. As shown in 
Figure 4, SmCl3@SWCNT-mAb (4a) was found to maintain Cetuximab efficiently immobilized and 
recognized by the secondary antibody, which was not the case of non-covalent complex 
SmCl3@SWCNT/mAb (5a). Even if both compounds seem to be internalized by U87-EGFR+, it 
could be hypothesized that part of the mAb on the non-covalent conjugate dissociates from the 
CNTs and binds the EGFR. As a consequence, the flow cytometry signal might originate from free 
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released Cetuximab internalized by the cells.41 In this way, we can obtain a signal in the flow 
cytometry analysis due to the presence of Cetuximab within the cells, which does not necessarily 
mean the presence of the whole CNT compound in contact with the cells. This could also explain 
the results obtained by TGA (Figure 2) and gel electrophoresis (Figure 3). In the first 
characterization, a similar loading of antibody is detected for covalent (4a) and non-covalent (5a) 
coupling. However, in the second one, the difference observed in the gel bands between both 
compounds is due to the fact that the non-covalent interaction allows the dissociation of the mAb 
from the tubes which is not possible in the case of the covalent bond. Similar results were obtained 
by the analysis of the mean fluorescence intensity data (see ESI Figure S8). The histograms point 
out the same outcomes observed by analyzing the percentages and do not allow to make a clear 
difference between the amount of SmCl3@SWCNT-mAb (4a) and SmCl3@SWCNT/mAb (5a) that 
bound and/or entered the cells.  
The previous experiments evidenced the presence of the antibody onto the nanotubes and they 
supported the specific targeting effect provided by the mAb to the CNTs. To further confirm these 
results, we decided to determine the content of samarium in the cells treated with the covalent 
conjugate SmCl3@SWCNT-mAb (4a), which represents an indirect measurement of the uptake. 
For this purpose, U87-EGFR+ and CHO were treated with 25 μg/ml of SmCl3@SWCNT-mAb (4a). 
After 24 hours the cells were washed, collected and the intracellular Sm content was measured by 
inductively coupled plasma atomic emission spectrometry (ICP-AES). A higher concentration in 
comparison to the flow cytometry analysis was used for this experiment in order to be above the 
quantification limits. 
The results shown in Table 1 are in good agreement with the previous experiments. It can be 
observed that a more efficient delivery of the metal contained inside the nanotubes was obtained in 
the case of U87-EGFR+. Even if a certain amount of Sm was found also in CHO cells, suggesting 
that a small degree of non-specific uptake occurred, the values of Sm content per cell clearly 
highlight that U87-EGFR+ cells were more efficient in binding and internalizing the SWCNTs, 
proving the specific targeting effect of the antibody-functionalization and the ability of the SWCNTs 
to accumulate intracellularly. 
 
Table 1 ICP-AES results indicating the Sm content in CHO and U87 cells after incubation for 24 hours with 
SmCl3@SWCNT-mAb (4a) (25 μg/ml) or without SWCNTs (Ø for control experiments). 
Cell line Entry Sm (pg/cell) 
CHO Ø < 0.10 
CHO SmCl3@SWCNT-mAb (4a) 1.59 ±  0.04 
U87 Ø < 0.10 
U87 SmCl3@SWCNT-mAb (4a) 5.60 ±  0.08 
 
Cytotoxicity of CNTs in U87-EGFR+ and CHO cells 
To confirm the uptake abilities of CNTs and to assess their effect on the cells,  SmCl3@SWCNT-
NH2 3a, SmCl3@SWCNT-mAb 4a and SmCl3@SWCNT/mAb 5a were incubated with U87-EGFR+ 
and CHO cells at 10, 50 and 100 μg/mL for 24 h in order to test potential cytotoxicity (see ESI 
Figure 9). The intracellular LDH content of both cell lines was measured after 24 h of incubation 
and 10% DMSO was used as positive control. No significant reduction of viability was observed for 
the different compounds at 10, 50 and 100 μg/mL. 
Synthesis and uptake of fluorescently-labeled SWCNT-antibody conjugates 
To further investigate the interactions of filled SWCNTs with cells and to assess the internalization 
mechanism, we decided to derivatize the amino-functionalized CNTs with a fluorescent dye. In 
order to mimic the previously synthesized mAb-functionalized SWCNTs, we designed a strategy 
based on the conjugation of a labeled antibody onto the nanotubes. By attaching the dye (i.e. 
cyanine 5, Cy5) to the amino groups of Cetuximab and then tethering the labeled Cetuximab to the 
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filled amino-functionalized SWCNTs (3b) via the carboxylic groups, we could exploit non-
competing binding sites of the antibody. Cy5 was pre-activated to introduce the reactive NHS-ester 
and then directly added to a buffer solution of Cetuximab for the coupling (see ESI Scheme S3). 
The labeled antibody [mAb(Cy5)] was thoroughly purified by size-exclusion chromatography and 
dialysis, to remove the unreacted mAb and Cy5. The degree of labeling (DL) estimated by UV-Vis 
spectroscopy was 4.4, meaning that an average of 4.4 molecules of Cy5 was bound to one 
molecule of Cetuximab. For the immobilization of mAb(Cy5) onto the nanotubes, a batch of 
SWCNTs filled with LuCl3 was employed. We have decided to use an alternative filled SWCNTs to 
prove the versatility of our construct. LuCl3@SWCNTs (1b) were previously functionalized by the 
nitrene reaction and phthalimide-deprotected following the previous protocol (see Scheme 1). The 
amine loading of the so-obtained conjugate LuCl3@SWCNT-NH2 (3b) was 146 μmol/g 
(corresponding to 208 μmol/g of C) as estimated by Kaiser test. The labeled antibody mAb(Cy5) 
was then coupled to LuCl3@SWCNT-NH2 (3b) as previously described, affording LuCl3@SWCNT-
mAb(Cy5) (4b) (see ESI Scheme S4). During the washing steps (centrifugation, supernatant 
removal and SWCNT re-dispersion), it was possible to verify the thorough removal of non-reacted 
mAb by UV-Vis spectroscopy, thanks to the intense UV adsorption of Cy5. The loading of antibody 
estimated by comparing the TG weight loss of LuCl3@SWCNT-mAb(Cy5) (4b) with that of the 
aminated precursor is 179 mg/g (311 mg/g of C) (see ESI Figure S10). The characterization was 
also performed by gel electrophoresis, and the output is in agreement with the previous results, 
confirming the covalent conjugation of the antibody (see ESI Figure S11). 
The newly synthesized fluorescent conjugate represents a useful tool to allow the assessment of 
the possible entry mechanisms of the CNTs in a quantitative manner by flow cytometry, as well as 
their intracellular distribution via confocal microscopy. In order to assess a passive and/or an 
energy-dependent uptake mechanism, U87-EGFR+ and CHO cells were treated at 37 °C or 4 °C 
for 2 hours with 1, 10 or 25 μg/ml LuCl3@SWCNT-mAb(Cy5) (4b) and analyzed by flow cytometry. 
As displayed in Figure 7, once again, SWCNTs are targeted to U87-EGFR+ cells. In these cells, 
regarding the percentage of cells that internalized the SWCNTs, no differences were detected 
between 37 °C and 4 °C. However, when analyzing the mean fluorescence intensity (see ESI 
Figure S12), the blocking of active mechanisms at 4 °C decreased the amount of SWCNTs that 
were able to enter U87-EGFR+ cells. In the case of CHO cells, the nanotubes were not able to 
bind or to enter the cells at the lower temperature, but they did it to a low extent in a concentration 
dependent manner at 37 °C. 
 
Figure 7 Bars represent the % of Cy5 positive U87-EGFR+ or CHO cells after 2 h incubation at 37 °C or 4 °C with 1, 10 
or 25 μg/ml of LuCl3@SWCNT-mAb(Cy5) (4b). Error bars represent the SD (n=3). **p<0.01.  
 
In addition, the fluorescent labeling also allowed us to follow the CNT conjugate 4b inside the cells 
once internalized. From the confocal microscopy images obtained after the treatment of CHO and 
U87-EGFR+ cells with 25 μg/ml of LuCl3@SWCNT-mAb(Cy5)  (Figure 8), the results of the uptake 
experiment can be visually proved. At 37 °C, a higher amount of fluorescent SWCNTs can be 
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observed inside U87-EGFR+ cells in comparison to CHO cells, whereas no differences are visible 
between the fluorescence at 4 °C or 37 °C in U87-EGFR+ cells. 
 
Figure 8 Fluorescence images of CHO and U87-EGFR+ cells treated for 2 hours with 25 μg/ml LuCl3@SWCNT 
mAb(Cy5) (4b) at 4 °C or 37 °C. Red color corresponds to the Cy5 on the nanotubes, while blue color represents the 
stained nuclei. 
Both experiments show that the antibody functionalization allows the SWCNTs to enter the cells 
actively as well as passively since they are able to be internalized at 4 °C, a temperature known to 
block endocytosis. On the contrary, in the case of CHO cells, functionalized SWCNTs seem to 
enter via an active mechanism as they only show low levels of cellular uptake at 37 °C. As it has 
been previously reported, functionalized CNTs can enter the cells via both an active endocytosis 
and by the so-called “nanoneedle” mechanism, a passive translocation into the cytoplasm.42 The 
adoption of two different mechanisms could be due to the fact that the absence of a targeting in the 
case of CHO cells could delay the interaction of the CNTs with the plasma membrane, allowing the 
formation of clusters of CNTs. As previously suggested by Mu et al.,43 clustered CNTs would not 
be able to directly cross the cell membrane and they may need to be endocytosed. The use of a 
passive mechanism remains in accordance to previously published results.42,44–46 Consequently 
there is no need of endocytosis for the uptake of SWCNTs although, when available, it may favor 
the internalization.  
CONCLUSION 
In summary, we have achieved the filling and sealing of purified SWCNTs with two radionuclide 
analogues (SmCl3 and LuCl3) and investigated their reactivity toward nitrene cycloaddition with an 
organic azide. We succeeded in the functionalization of both Sm- and Lu-filled CNTs with a 
biocompatible linker and a targeting monoclonal antibody (Cetuximab) and proved the targeting 
efficacy of this novel carrier toward cancer cells overexpressing the EGF receptor. Researches on 
the functionalization of CNTs filled with radioactive material aimed at evaluating the biodistribution 
and therapeutic effect of these conjugates in vivo will follow in the next future. With this work we 
propose that the encapsulation of therapeutic or imaging radioisotopes within CNTs and 
subsequent surface functionalization with targeting ligands could offer a stable and efficient way for 
the selective delivery of radioisotopes at ultrasensitive doses for therapeutic or diagnostic 
purposes. After sealing the chosen radionuclides, the external walls of the closed-ended filled 
carbon nanotubes can be decorated with biologically active molecules in order to convey specific 
targeting properties and enhance their biocompatibility. We believe that our results will inspire the 
development of novel nanomaterials for biomedical applications in the areas of cancer diagnosis 
and therapy. 
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EXPERIMENTAL PART 
Materials and Methods 
Chemical vapor deposition grown single-walled carbon nanotubes (SWCNTs) were supplied by 
Thomas Swan & Co. Ltd. (Elicarb®). The as-received material also contained a fraction of double-
walled carbon nanotubes (DWCNTs), amorphous carbon, graphitic particles (carbonaceous 
crystalline materials having few graphitic layers), and some metal particles. The presence of 
DWCNTs in the samples has been recently analyzed by Raman spectroscopy [M. Kierkowicz, E. 
Pach, A. Santidrián, E. Tobías-Rossell, M. Kalbáč, B. Ballesteros and G Tobias, ChemNanoMat, 
DOI: 10.1002/cnma.201500207.]. Both samarium (III) chloride and lutetium (III) chloride were 
purchased from Sigma Aldrich (anhydrous, powder, 99.99% trace metals basis). The chemicals 
and solvents were obtained from commercial suppliers and used without further purification. 
Cetuximab was obtained from KCL (London) as pharmaceutical formulation Erbitux® (C = 5 
mg/mL). For the fluorescent tagging, cyanine 5 (Cy5) was provided by the group of Anthony 
Romieu (Université de Bourgogne in Dijon). The solvents used for synthesis were analytical grade. 
When anhydrous conditions were required, high quality commercial dry solvents were used. Water 
was purified using a Millipore filter system MilliQ®. When stated, suspensions were sonicated in a 
water bath (20 W, 40 kHz). For the labeled antibody purification, the column was assembled by 
packing Sephadex G-25 Fine (GE Healthcare) with PBS buffer. For CNT filtration, PTFE 
membrane from Millipore were employed. If not differently specified, dialysis of CNT compounds 
was carried out employing membrane with MWCO 12000-14000 Da, purchased from Spectrum 
Laboratories, Inc. Mini-dialysis and buffer exchange were performed in Slide-A-Lyzer dialysis tubes 
(10000 MWCO) from Thermo Scientific. Protein concentration was carried out with Amicon Ultra-
15 centrifugal filters (10000 MWCO) from Millipore. Centrifugation was performed either using an 
Eppendorf 5804 R apparatus, or a Beckman Avanti J-25 centrifuge equipped with JS-7.5 rotor. The 
UV-Vis analyses were performed on a Varian Cary 5000 spectrophotometer and the Kaiser test 
was performed according to reported procedures.47,48 TGA under flowing air was performed on a 
TA Instrument Q5000 IR (for LuCl3 related samples) and on a Netzsch STA 449 F1 Jupiter (for 
SmCl3 related samples). Measurements were performed on about 5 mg of sample under flowing 
air by heating at 10 °C/min up to 900 °C. TGA under inert atmosphere was performed on a TGA1 
(Mettler Toledo) apparatus from 30 °C to 900 °C with a ramp of 10 °C·min-1 under N2 using a flow 
rate of 50 mL/min and platinum pans. In this case, the estimation of the degree of functionalization 
by TGA was done by taking weight loss values at 650 °C, because up to 600 °C strong weight 
losses were still occurring. For TGA of the CNT-antibody conjugates, an aliquot of the conjugate in 
PBS was previously dialyzed against deionized water to remove the buffer salts and lyophilized. 
TEM analyses were performed on a Hitachi H7500 microscope (Tokyo, Japan) with an 
accelerating voltage of 80 kV, equipped with an AMT Hamamatsu camera (Tokyo, Japan). 
HAADF-STEM images were acquired at 20 kV on a FEI Magellan XHR 400L SEM equipped with a 
dedicated STEM detector. HRTEM micrographs and EDX spectra were acquired on a FEI Tecnai 
G2 F20 operated at 200 kV and equipped with an EDAX super ultra-thin window (SUTW) X-ray 
detector. Samples were dispersed in ethanol and deposited on lacey carbon Cu TEM grids (Agar). 
 
Synthesis and characterization of the CNT conjugates  
Preparation of SmCl3 filled SWCNTs (SmCl3@SWCNTs 1a) 
As-received SWCNTs were purified by steam treatment following a previously reported protocol.31 
Briefly, SWCNTs were spread inside a silica tube which was then placed into a furnace alumina 
tube. Steam was introduced by bubbling argon through a flask containing hot distilled water. The 
whole system was initially purged with argon, to remove atmospheric air, before heating the 
furnace to 900 °C during 4 h to allow the purification of the material. The solid powder was 
collected and treated with 6 M HCl (Panreac) to dissolve the exposed metal nanoparticles. The 
purified SWCNTs were collected by filtration through a 0.2 μm polycarbonate membrane and 
thoroughly washed with water until neutral pH. The sample was oven-dried at 80 °C overnight. 
Purified SWCNTs were then mixed with samarium (III) chloride (w/w 1:10 respectively) and grinded 
with an agate mortar and pestle inside a glovebox until the mixture presented a homogeneous 
color. The resulting mixture was then vacuum sealed inside a silica ampoule and annealed at 900 
°C for 12 h. After cooling down the sample, the silica tube was opened and the material was stirred 
in water at 80 °C to remove the non-encapsulated SmCl3 external to the SWCNTs. 
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Preparation of LuCl3 filled SWCNTs (LuCl3@SWCNTs 1b) 
As-received SWCNTs were dispersed in fresh piranha solution (H2SO4/H2O2, 4:1) at a 
concentration of 1 mg/mL.49 The solution was stirred for 2 h at r.t. and the reaction then quenched 
with distilled water. The pH of the solution was adjusted until neutral. The sample was filtered on a 
polycarbonate membrane and dried in the oven at 80 °C overnight. Next, the SWCNTs were 
treated with steam for 1 h at 900 °C and refluxed in 6 M HCl at 110 °C overnight. The solid sample 
was collected by filtration and rinsed with distilled water until neutral pH. The purified SWCNTs 
were filled with lutetium (III) chloride by molten phase capillary filling. SWCNTs were mixed with 
LuCl3 (w/w 1:10) and grinded with an agate mortar in an argon-filled glovebox. The mixture was 
sealed under vacuum inside a silica tube. The sample was then annealed in a horizontal furnace at 
960 °C during 12 h. The resulting sample contained filled closed-ended nanotubes30 and external 
crystals of LuCl3. The non-encapsulated material was removed by washing the sample in hot 
water. 
 
Synthesis of the organic precursor S3 
The synthesis of the organic azide S3 was carried out following a reported procedure (see ESI for 
details).37 
 
Fluorescent labeling of Cetuximab [mAb(Cy5)] 
A 10 mg/mL solution of Cy5 was prepared by dissolving Cy5 (5.99 mg, 7.04 μmol) in dry DMF (500 
μL), under argon. DIEA (12 µL) and 40 μL of a 0.15 M solution of TSTU in dry DMF (corresponding 
to 7 μmol of TSTU) were then added to the Cy5 and the reaction mixture was stirred at r.t. for 4 h, 
in the dark. The activated Cy5 (300 μL, ca. 3 mg) was added to a 5 mg/mL solution of Cetuximab 
in PBS (6 mL) at pH 8 (adjusted with 1 M NaHCO3) and gently stirred for 2 h, in the dark. The 
reaction mixture was then filtered through a Sephadex G-25 column with PBS (pH 7.4) as elution 
buffer and the fractions corresponding to the mAb(Cy5) were joined together and concentrated in 
an Amicon centrifugal filter (MWCO 10000). By measuring the UV-Vis absorbance of the 
conjugate, the degree of labeling (DL) was calculated according to the formula reported in ESI and 
corresponded to 4.4 molecules of Cy5 per mAb. 
 
Synthesis of SmCl3@SWCNT-NH2 (3a) and LuCl3@SWCNT-NH2 (3b) 
In a flame-dried Schlenk tube, filled SWCNTs (1a or 1b) (30 mg) were dispersed in dry NMP (25 
mL) by sonicating for 15 min under argon. A solution of azide S3 (560 mg) in dry NMP (5 mL), was 
then added to the CNT dispersion by syringe and the mixture was stirred at 200 °C for 12 h. The 
cooled mixture was then diluted with EtOH (15 mL) and filtered (0.1 μm). The CNTs recovered on 
the filter were washed with EtOH (x 1), MeOH (x 2) and acetone (x 2) and dialyzed for 48 h against 
ddH2O. The dialyzed nanotubes were recuperated by filtration, washed with MeOH (x 1) and 
acetone (x 1) and finally dried under vacuum. The degree of functionalization estimated from the 
weight loss comparison with pristine filled SWCNTs (1a, 1b) is 17.1% for SmCl3@SWCNT-Pht (2a) 
and 17.2% for LuCl3@SWCNT-Pht (2b). 
For the deprotection, CNTs (28 mg) were dispersed in EtOH (25 mL) by sonicating for 10 min, and 
afterwards treated with hydrazine hydrate (3 mL). The dispersion was stirred at r.t. for 2 h, and 
then diluted with EtOH (15 mL) and filtered (0.1 µm). The recovered CNTs were washed with 
MeOH (x 2) and acetone (x 2), and finally dried under vacuum. The free amine loading calculated 
by Kaiser test is 90 μmol/g for SmCl3@SWCNT-Pht (3a) and 146 μmol/g for LuCl3@SWCNT-Pht 
(3b). 
 
Synthesis of SmCl3@SWCNT-mAb (4a) and SmCl3@SWCNT/mAb (5a) 
An aliquot of Erbitux® (2 mL) was submitted to buffer exchange in a Slide-a-Lyzer Mini Device 
(MWCO 10000) against MES buffer pH 7, in order to bring Cetuximab in the required buffer 
medium. MES buffer 50 mM was prepared by dissolving MES (9.76 g) in ddH2O (800 mL) and pH 
was adjusted to 7 with 10 N NaOH before bringing the solution to 1 L volume. 
Conjugate 3a (16 mg) was dispersed in DMF (1.3 mL) by sonicating for 15 min in a centrifuge 
plastic tube. A solution of EDC×HCl (6 mM) and NHSS (4.4 mM) in MES (2.5 mL) was then added 
to the dispersion under sonication. After 5 min, Cetuximab (1 mg/mL in MES, 11 mL) was added 
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and the mixture was gently stirred at r.t. for 24 h. The reaction mixture was homogenized by 
sonicating for 30 sec and the CNTs were precipitated by centrifugation (4500 rpm, 10 min, 15 °C). 
The supernatant was removed, the CNTs were re-dispersed in PBS (20 mL) by sonicating for 10 
min. Centrifugation, buffer removal and re-dispersion were repeated at least 3 times in order to 
remove non-reacted antibody. The CNT dispersion was then dialyzed (MWCO 300000 Da) against 
PBS for 24 h. The obtained 4a was finally stored at 4 °C in PBS solution (3.5 mg/mL). The loading 
of antibody estimated by TGA is 250 mg/g. 
For the control reaction, the same procedure was carried out proportionally on a smaller amount of 
3a (3.1 mg) and without addition of EDC×HCl and NHSS. The obtained SmCl3@SWCNT/mAb (5a) 
was stored at 4 °C in PBS solution (1.57 mg/mL). The loading of antibody determined by TGA is 
200 mg/g. 
 
Synthesis of LuCl3@SWCNT-mAb(Cy5) (4b) 
The labeled antibody [mAb(Cy5)] (8 mL, 3.8 mg/mL) was submitted to buffer exchange in a Slide-
a-Lyzer Mini Device (MWCO 10000) against 50 mM MES buffer pH 7. Conjugate 3b (4 mg) was 
dispersed in DMF (400 μL) by sonicating for 15 min in a centrifuge plastic tube. A solution of 
EDC×HCl (6 mM) and NHSS (4.4 mM) in MES (800 μL) was then added to the dispersion under 
sonication. After 5 min, mAb(Cy5) (0.96 mg/mL in MES, 2.8 mL) was added to the CNT dispersion 
and the mixture was gently stirred at r.t. for 24 h. The reaction mixture was homogenized by 
sonicating for 30 sec and the CNTs were precipitated by centrifugation (4500 rpm, 10 min, 12 °C). 
The supernatant was removed, the CNTs were re-dispersed in PBS (3 mL) by sonicating for 10 
min. Centrifugation, buffer removal and re-dispersion were repeated 4 times and the decanted 
fractions were analyzed by UV-Vis spectroscopy to check the absence of non-reacted mAb(Cy5). 
The CNT dispersion was then dialyzed (MWCO 300000 Da) against PBS for 24 h. The obtained 
conjugate 4b was stored at 4 °C in PBS solution. The loading of antibody was determined by TGA 
and corresponds to 179 mg/g. 
 
Gel electrophoresis 
Gel electrophoresis was performed using Mini-PROTEAN® TGXTM 4-20% Tris-glycine gels 
purchased by Bio-Rad Laboratories (Hercules, California). Tris-glycine buffer was used to fill the 
tank. Prior to loading, the samples were added with Laemmli buffer for non-reducing conditions. 
The first well was always loaded with the protein ladder. The gel was run at a voltage of 150 V for 
ca. 60 min and then stained overnight with Coomassie blue. Finally, the staining solution was 
removed and the gel extensively washed with distilled water to allow the visualization of the protein 
bands. 
 
 
Immunostaining 
For the colloidal gold immunostaining, 20 μL of CNT dispersion (20 μg/mL) in PBS were drop-
casted on the TEM grids and allowed to dry in air. The TEM grids were first incubated with 
acetylated BSA in ultrapure UPS-WFI water (1% w/w) for 45 min and then incubated for 2 h with 20 
μL of staining solution (anti-human IgG/AuNP or anti-rabbit IgG/AuNP). The staining solutions were 
prepared as following: the secondary IgG/AuNP was dissolved in BSA (0.1% w/w in PBS) in a 1:50 
volume ratio. After incubation, the excess of immunoglobulin was rinsed away by incubating the 
grids with 300 μL of PBS for 5 min (3 times), and finally with 300 μL of ddH2O. After drying in air, 
the grids were observed by TEM and STEM. 
 
Biological investigations 
Cell culture 
U87-EGFR+ cells were cultured under controlled atmosphere (37°C, 5% CO2) in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% FBS, 100 U/ml gentamycin and 1% 
Penicillin-Streptomycin, whereas for CHO cell line RPMI 1640 supplemented with 10% FBS and 
1% Penicillin-Streptomycin was used. When confluency reached 70-80%, cells were tripsinized, 
and reseeded in 24 well plates at a density of 105 cells/well and allowed to adhere overnight (37 
°C, 5% CO2) prior to CNT addition. 
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Examination of EGFR expression by Western blot analysis 
CHO and U87-EGFR cells were cultured in T75 flask. At 80% confluency, cells were rinsed twice 
with ice-cold PBS, incubated with 300 µL ice-cold RIPA lysis buffer (150 mM NaCl, 0.1%Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris-HCl, pH 8) containing protease inhibitor 
(cComplete Ultra, Roche Diagnostics GmbH, Germany). Cells were scrapped out and collected 
into a vial. After 30 min - 1 h incubation on ice, cell solutions were centrifuged at 17949xg for 30 
min and the supernatants were collected. The protein concentrations cell samples were 
determined by BCA assay. Proteins (30 μg) from each sample was resolved in 8 % SDS-PAGE 
gels and transferred to Hybond ECL nitrocellulose membranes (GE Healthcare, UK). The 
membrane was blocked in 3% bovine serum albumin (Sigma-Aldrich, UK) at room temperature for 
1 h and then co-incubated with rabbit monoclonal anti-EGFR antibody at 1:1000 dilution (#4267, 
Cell Signalling Technology, USA) and anti-GAPDH antibody at 1:5000 dilution (#14C10, Cell 
Signalling Technology, USA) overnight on ice. After washing, the membrane were then incubated 
with the secondary antibody, horseradish peroxidase linked anti-rabbit antibody (#7074, Cell 
Signalling Technology, USA) at 1:3000 dilution for 2 hour at room temperature. Protein bands were 
detected using chemiluminescent kits (Immun-StarTM Chemiluminescent Kit, BioRad, UK) and 
imaged by ChemiDoc MP imaging system and Image Lab software (BioRad, UK). GAPDH was 
used as an internal reference (house-keeping) gene.  
Uptake studies in vitro by flow cytometry 
U87-EGFR+ and CHO cells were treated with 10 µg/ml of SmCl3@SWCNT-NH2 (3a), 
SmCl3@SWCNT-mAb (4a) and SmCl3@SWCNT/mAb (5a). As a positive control a concentration of 
2.5 µg/ml of Cetuximab (Erbitux®, Merck KGaA) was used. One and 3 hours after the addition of 
the CNTs, cells were washed twice with PBS and fixed with 4% paraformaldehyde (PFA) for 15 
min at room temperature. Subsequently, cells were permeabilized with Triton X-100 (0.1% in PBS) 
for 10 min, blocked with 1% BSA for 30 min at room temperature. Finally, cells were incubated for 
2 h with a fluorescent Cy3-goat anti-human IgG (H+L) (109-165-088-JIR, Stratech Scientific Ltd) 
secondary antibody to track Cetuximab. The percentage of Cy3 positive cells and the mean 
fluorescent intensity were determined by acquiring at least 10,000 events using a FACSCalibur 
flow cytometer (BD, Franklin Lakes, NJ) and analyzing the data with Flowing Software 2.5.1 
 
ICP-AES 
U87-EGFR+ and CHO cells were seeded in quadruplicate onto 24-well plates at a density of 105 
cells/well and allowed to adhere overnight prior to exposure to SmCl3@SWCNT-mAb (4a) (25 
μg/ml). 24 h later cells were extensively washed with cold PBS, tripsinized, collected and stored in 
a glass vial until analysis. ICP-AES analyses were performed on an Agilent 7500ce apparatus. 
 
Modified LDH assay 
In order to assess the effect of CNTs on cell viability and proliferation, intracellular lactate 
dehydrogenase (LDH) content of U87-EGFR+ and CHO cells exposed to CNTs was measured 
with the following protocol. Cells were seeded at 1x104 cells per well in 96-well plates, incubated 
overnight at 37° C with 5% CO2 before being treated with CNTs at 10, 50 or 100 µg/ml in serum 
free DMEM media. After 4 h, cells were supplemented with serum (10% v/v) and incubated at 37° 
C with 5% CO2 for an overall duration of 24 h. After treatment, cell supernatants were discarded 
and cells were lysed after incubation with 200 µL of 0.9% of Triton X-100/phenol-free DMEM media 
solution for 1 h at 37° C. Lysates were centrifuged at 40,000xg for 10 min and the resulting pellets 
containing both CNT entrapped inside cells and cell debris were discarded. A mix of 50 µL of cell 
lysate supernatant with 50 µL of Substrate Mix Solution (CytoTox® kit) was incubated at room 
temperature and in the dark for 15 min before adding 50 µL of Stop Solution (CytoTox® kit). Blank 
contained 50 µl of lysis buffer, 50 µl of substrate mix solution and 50 µl of stop solution. The 
absorbance was read at 490 nm with a microplate reader (Fluostar Omega®) obtained from BMG 
LABTECH (Germany).  The following formula was used to calculate the percentage of intracellular 
LDH: % of intracellular LDH = (A490nm of treated cells – A490nm of blank) / (A490nm of untreated cells – 
A490nm of blank) x 100. Results were expressed as mean ± SD (n=3). 
 
Cellular uptake with fluorescent CNTs 
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U87-EGFR+ and CHO cells were seeded onto 24 well/plates (105 cells/well) and allowed to adhere 
overnight. Afterwards, cells were treated with 1, 10 or 25 μg/ml of LuCl3@SWCNT-mAb(Cy5) (4b) 
and incubated either at 4 °C or at 37 °C for 2 h to compare the non-active and active uptake 
mechanisms, respectively. Cells were then extensively washed with cold PBS, tripsinized, 
collected and analyzed with Gallios flow cytometer (Beckman Coulter, Villepinte, France). The 
percentage of fluorescent cells and their mean fluorescent intensity was determined by acquiring at 
least 10,000 events and analyzing the data with Flowing Software 2.5.1. 
 
Confocal microscopy experiment 
Cells were seeded onto polystyrene culture chambers (Falcon 354108) and allowed to adhere 
overnight (105 cells/well). The conjugate LuCl3@SWCNT-mAb(Cy5) (4b) (25 μg/ml) was then 
added and incubated for 2 h either at 4 °C or 37 °C. Cells were then extensively washed with cold 
PBS, fixed with 4% PFA and treated with DAPI (0.1% in PBS) in order to stain the nuclei of the 
cells. Images were obtained with an Axio Observer Z1 microscope (Zeiss) connected to a Spinning 
Disk Confocal head (Yokogawa) and ImageJ software was used for further analyses. 
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